Get news updates from AACR Annual Meeting News
Subscribe below to get email updates from AACRMeetingNews.org
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
Presenters Caroline Dive, BPharm, PhD, Alberto Bardelli, PhD, and Sarah-Jane Dawson, MBBS, PhD, discussed different uses for this evolving field.
(From left) Crystal L. Mackall, MD, Hagop M. Kantargian, MD, and Carl H. June, MD, PhD, FAACR, discussed how to decide between monoclonal antibodies, CAR-T therapies, or a combination.
(From left) Steven Goodman, MD, MHS, PhD, Mi-Ok Kim, PhD, and Motomi Mori, PhD, discussed current schools of thought regarding their use or misuse in studies.
“Now, more than ever, it is imperative that our innovative work continues, because patients with cancer around the world are counting on us,” said AACR CEO Margaret Foti, PhD, MD (hc).
Monday’s plenary features presentations from (clockwise, from left) Serena Nik-Zainal, MD, PhD, Ross L. Levine, MD, Jérôme Galon, PhD, and Garry P. Nolan, PhD.
(Clockwise, top left) Samuel F. Bakhoum, MD, PhD, Karlene A. Cimprich, PhD, Stephen P. Jackson, PhD, and David Pellman, PhD, discussed its viability as a novel therapy target.
Updates on phase III trials came from (clockwise, top left) Matthew J. Matasar, MD, Jessica Hassel, MD, Patrick M. Forde, MBBCh, and Georgina V. Long, PhD, MBBS.
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
(Clockwise, from top left) Katelyn T. Byrne, PhD, Brett G.M. Hughes, MSci, MBBS, Sanaz N. Ghafouri, MD, Jason Alan Chesney, MD, PhD, and Richard S. Finn, MD, will present during the session.
April 5-10, 2024
San Diego Convention Center
San Diego, California